| Literature DB >> 30310447 |
Maria Lorenza Muiesan1, Claudia Agabiti-Rosei1, Anna Paini1, Massimo Salvetti1.
Abstract
In recent years, serum uric acid (SUA) as a determinant of cardiovascular (CV) risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia SUA are at increased risk of cardiac, renal and vascular damage and CV events. There is now some evidence to suggest that urate-lowering treatment may reduce CV risk in this group and, thus, may represent a new strategy in risk reduction.Entities:
Keywords: AF; CV disease; Uric acid; heart failure; target organ damage; xanthine-oxidase inhibitors
Year: 2016 PMID: 30310447 PMCID: PMC6159425 DOI: 10.15420/ecr.2016:4:2
Source DB: PubMed Journal: Eur Cardiol ISSN: 1758-3756